Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets
Where Rebates Eat Into Prices, Volume Makes Up The Difference
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
